alexa Neural Precursor Cells|OMICS International|Anatomy And Physiology: Current Research

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Neural Precursor Cells

" Of all stem cell types, ESCs currently show the greatest potential for the widest range of cell therapies. The pluripotency and plasticity of ESCs isolated from inner cell masses have been demonstrated conclusively by many pioneering studies. However, immune rejection and ethical controversy are major hurdles for clinical application of ESCs. Compared to other stem cells, NPCs are already committed to a neural fate and hence will be easier to differentiate into mature neural phenotypes. Therefore, they have been widely used in neurological disorder repair. Nevertheless, the difficulty in access to human tissues for cell isolation and limited expansion potential of NPCs hamper their application in the clinical setting. Other cell types such as Schwann cells, olfactory ensheathing cells, and bone marrow stromal cells are also subject to various limitations in differentiation potency and self-renewal capacity. Collectively, current cell therapies lack clinical feasibility due to limited cellular availability, ethical concerns, and the need for immunosuppression. A recent breakthrough in stem cell biology is the finding of induced pluripotent stem cells (iPSCs) technology. Using iPSCs technology, researchers can achieve embryonic-like cells without the ethical dilemma. iPSCs, have the advantage of eliminating immune rejection concerns as they are obtained from host as well as have pluripotent behaviour. The generation of iPSCs from a patient’s own somatic cells would potentially allow for a plentiful source of cell therapeutics for autotransplantation. Furthermore, the use of iPSCs largely circumvents political, ethical, and logistical roadblocks previously associated with other cell transplantation. Therefore, they are considered to be an ideal cell source for transplantation therapy for the treatment of SCI. (Huanxing Su and Wutian Wu- Cell-Based Therapy for Spinal Cord Injury) "
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2014